Stem Cell Manufacturing Market - 2024-2032

January 2026 | 218 pages | ID: S07EF90113D1EN
DataM Intelligence

Abstracts

The Stem Cell Manufacturing Market was valued at US$ 16.23 billion in 2024 and is anticipated to reach US$ 40.40 billion by 2032, at a CAGR of 0.115 from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Stem Cell Manufacturing Market.

This report delivers a comprehensive overview of the Stem Cell Manufacturing Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Stem Cell Manufacturing Market. The Stem Cell Manufacturing Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2024–2032.

Stem Cell Manufacturing Market Scope:

By Product

• Adult Stem Cells (ASCs)
• Human Embryonic Stem Cells (HESCs)
• Induced Pluripotent Stem Cells (iPSCs)
• Very Small Embryonic-Like Stem Cells
• Consumables
• Instruments

By Application

• Regenerative Medicine
• Drug Discovery and Development
• Research Applications
• Cell and Tissue Banking

By Technology

• Cell Acquisition
• Cell Production
• Cryopreservation
• Expansion and Sub-Culture

By Therapy Type

• Autologous Therapy
• Allogenic Therapy

By End-User

• Pharmaceutical and Biotechnology Companies
• Hospitals and Clinics
• Stem Cell Banks
• Research Institutions

Key Players

• Thermo Fisher Scientific Inc.
• Merck KGaA
• Lonza Group Ltd.
• DH Life Sciences, LLC.
• Sartorius AG
• Becton, Dickinson and Company (BD)
• Eppendorf SE
• Corning Incorporated
• Bio-Rad Laboratories, Inc.
• Fujifilm Holdings Corporation (Cellular Dynamics)

Major Highlights

This report delivers a comprehensive overview of the Stem Cell Manufacturing Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Stem Cell Manufacturing Market. The Stem Cell Manufacturing Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2024–2032.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Regional Analysis:

• North America (U.S., Canada, Mexico)
• Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
• Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
• South America (Colombia, Brazil, Argentina, Rest of South America)
• Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Partner Identification

• Increase Your Customer Base by 3X using our Partner Identification tool
• Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.
• Identify high potential M&A targets based on synergies, market positioning and growth trajectory.
• Prioritize partners by strategic fit rather than general capability.

Why Choose DataM?

• Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.
• Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.
• White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.
• Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.
• Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.
• Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

Target Audience 2026

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Contents

1. METHODOLOGY AND SCOPE

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. DEFINITION AND OVERVIEW

3. EXECUTIVE SUMMARY

3.1. Snippet by Product
3.2. Snippet by Application
3.3. Snippet by Technology
3.4. Snippet by Therapy Type
3.5. Snippet by End-User
3.6. Snippet by Region

4. DYNAMICS

4.1. Impacting Factors
  4.1.1. Drivers
    4.1.1.1. Innovations in Stem Cell Manufacturing
    4.1.1.2. XX
  4.1.2. Restraints
    4.1.2.1. High Operational Costs
  4.1.3. Opportunity
  4.1.4. Impact Analysis

5. INDUSTRY ANALYSIS

5.1. Porter’s Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Patent Analysis
5.5. Regulatory Analysis
5.6. SWOT Analysis
5.7. Unmet Needs

6. BY PRODUCT

6.1. Introduction
  6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Product
  6.1.2. Market Attractiveness Index, By Product
6.2. Adult Stem Cells (ASCs)*
  6.2.1. Introduction
  6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  6.2.3. Hematopoietic Stem Cells (HSCs)
  6.2.4. Mesenchymal Stem Cells (MSCs)
  6.2.5. Neural Stem Cells
  6.2.6. Epithelial/Skin Stem Cells
6.3. Human Embryonic Stem Cells (HESCs)
6.4. Induced Pluripotent Stem Cells (iPSCs)
6.5. Very Small Embryonic-Like Stem Cells
6.6. Consumables
  6.6.1. Culture media
  6.6.2. Reagents
  6.6.3. Others
6.7. Instruments
  6.7.1. Bioreactors
  6.7.2. Incubators
  6.7.3. Cell Sorters
  6.7.4. Others

7. BY APPLICATION

7.1. Introduction
  7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  7.1.2. Market Attractiveness Index, By Application
7.2. Regenerative Medicine*
  7.2.1. Introduction
  7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Drug Discovery and Development
7.4. Research Applications
7.5. Cell and Tissue Banking

8. BY TECHNOLOGY

8.1. Introduction
  8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  8.1.2. Market Attractiveness Index, By Technology
8.2. Cell Acquisition*
  8.2.1. Introduction
  8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Cell Production
8.4. Cryopreservation
8.5. Expansion and Sub-Culture

9. BY THERAPY TYPE

9.1. Introduction
  9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
  9.1.2. Market Attractiveness Index, By Therapy Type
9.2. Autologous Therapy*
  9.2.1. Introduction
  9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Allogenic Therapy

10. BY END-USER

10.1. Introduction
  10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  10.1.2. Market Attractiveness Index, By End-User
10.2. Pharmaceutical and Biotechnology Companies*
  10.2.1. Introduction
  10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Hospitals and Clinics
10.4. Stem Cell Banks
10.5. Research Institutions

11. BY REGION

11.1. Introduction
  11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  11.1.2. Market Attractiveness Index, By Region
11.2. North America
  11.2.1. Introduction
  11.2.2. Key Region-Specific Dynamics
  11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
  11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  11.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    11.2.8.1. U.S.
    11.2.8.2. Canada
    11.2.8.3. Mexico
11.3. Europe
  11.3.1. Introduction
  11.3.2. Key Region-Specific Dynamics
  11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
  11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  11.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    11.3.8.1. Germany
    11.3.8.2. U.K.
    11.3.8.3. France
    11.3.8.4. Spain
    11.3.8.5. Italy
    11.3.8.6. Rest of Europe
11.4. South America
  11.4.1. Introduction
  11.4.2. Key Region-Specific Dynamics
  11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
  11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  11.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    11.4.8.1. Brazil
    11.4.8.2. Argentina
    11.4.8.3. Rest of South America
11.5. Asia-Pacific
  11.5.1. Introduction
  11.5.2. Key Region-Specific Dynamics
  11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
  11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  11.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    11.5.8.1. China
    11.5.8.2. India
    11.5.8.3. Japan
    11.5.8.4. South Korea
    11.5.8.5. Rest of Asia-Pacific
11.6. Middle East and Africa
  11.6.1. Introduction
  11.6.2. Key Region-Specific Dynamics
  11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
  11.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

12. COMPETITIVE LANDSCAPE

12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis

13. COMPANY PROFILES

13.1. Thermo Fisher Scientific Inc.*
  13.1.1. Company Overview
  13.1.2. Product Portfolio
    13.1.2.1. Product Description
    13.1.2.2. Product Key Performance Indicators (KPIs)
    13.1.2.3. Historic and Forecasted Product Sales
    13.1.2.4. Product Sales Volume
  13.1.3. Financial Overview
    13.1.3.1. Company Revenue’s
    13.1.3.2. Geographical Revenue Shares
    13.1.3.3. Revenue Forecasts
  13.1.4. Key Developments
    13.1.4.1. Mergers & Acquisitions
    13.1.4.2. Key Product Development Activities
    13.1.4.3. Regulatory Approvals etc.
  13.1.5. SWOT Analysis
13.2. Merck KGaA
13.3. Lonza Group Ltd.
13.4. DH Life Sciences, LLC.
13.5. Sartorius AG
13.6. Becton, Dickinson and Company (BD)
13.7. Eppendorf SE
13.8. Corning Incorporated
13.9. Bio-Rad Laboratories, Inc.
13.10. Fujifilm Holdings Corporation (Cellular Dynamics) (*LIST NOT EXHAUSTIVE)

14. APPENDIX

14.1. About Us and Services
14.2. Contact Us